Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.

Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y.

J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10.

PMID:
31821071
2.

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.

Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N.

Cancer Sci. 2020 Feb;111(2):571-579. doi: 10.1111/cas.14265.

3.

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N.

Cancer Chemother Pharmacol. 2020 Feb;85(2):449-459. doi: 10.1007/s00280-019-03992-2. Epub 2019 Nov 19.

PMID:
31745590
4.

[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].

Ohtake Y, Sudo K, Kojima Y, Seo T, Okuma H, Nishikawa T, Uno M, Uehara T, Ishikawa M, Tanioka M, Noguchi E, Shimomura A, Yonemori K, Kato T, Fujiwara Y, Tamura K.

Gan To Kagaku Ryoho. 2019 Oct;46(10):1525-1529. Japanese.

PMID:
31631133
5.

Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.

Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S.

Cancer. 2020 Jan 1;126(1):98-104. doi: 10.1002/cncr.32508. Epub 2019 Sep 19.

PMID:
31536651
6.

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan.

Yunokawa M, Sasada S, Takehara Y, Takahashi K, Shimoi T, Yonemori K, Ishikawa M, Kato T, Tamura K.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1051-1058. doi: 10.1007/s00280-019-03938-8. Epub 2019 Sep 4.

PMID:
31482227
7.

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.

Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.

Transl Oncol. 2019 Oct;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. Epub 2019 Aug 2.

8.

Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey.

Li CK, Dalvi R, Yonemori K, Ariffin H, Lyu CJ, Farid M, Gonzales-Santos JRN, Zhou Q, Bielack S, Brugieres L, Blondeel A, Essiaf S, Peccatori FA, Jezdic S, Stark DP, Douillard JY, Saloustros E, Mountzios G.

ESMO Open. 2019 Jun 6;4(3):e000467. doi: 10.1136/esmoopen-2018-000467. eCollection 2019.

9.

Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study.

Panizza CE, Lim U, Yonemori KM, Cassel KD, Wilkens LR, Harvie MN, Maskarinec G, Delp EJ, Lampe JW, Shepherd JA, Le Marchand L, Boushey CJ.

Nutrients. 2019 Jun 20;11(6). pii: E1386. doi: 10.3390/nu11061386.

10.

A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma.

Toki S, Kobayashi E, Yoshida A, Ogura K, Wakai S, Yoshimoto S, Yonemori K, Kawai A.

Bone Joint J. 2019 Jun;101-B(6):745-752. doi: 10.1302/0301-620X.101B6.BJJ-2018-1207.R1.

PMID:
31154837
11.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N.

Invest New Drugs. 2019 May 24. doi: 10.1007/s10637-019-00787-3. [Epub ahead of print]

PMID:
31124055
12.

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.

Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.

PMID:
31104192
13.

A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.

Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N.

Clin Pharmacol Ther. 2019 Oct;106(4):803-809. doi: 10.1002/cpt.1442. Epub 2019 Apr 29.

PMID:
30927439
14.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.

Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2.

15.

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.

Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8.

16.

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.

Intern Med. 2019 May 15;58(10):1423-1428. doi: 10.2169/internalmedicine.1118-18. Epub 2019 Feb 1.

17.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.

Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.

PMID:
30703739
18.

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.

Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, Oakley GJ, Sakaguchi S, Tamura K.

Cancer Sci. 2018 Dec;109(12):3962-3970. doi: 10.1111/cas.13846.

19.

Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.

Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Kobayashi Y, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y.

Oncologist. 2019 Feb;24(2):266-272. doi: 10.1634/theoncologist.2017-0511. Epub 2018 Sep 25.

20.

Biomonitoring an albumin adduct of the cooked meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in humans.

Bellamri M, Wang Y, Yonemori K, White KK, Wilkens LR, Le Marchand L, Turesky RJ.

Carcinogenesis. 2018 Dec 31;39(12):1455-1462. doi: 10.1093/carcin/bgy125.

PMID:
30247550
21.

SMARCB-1 deficient squamous cell carcinoma of a mediastinal cyst.

Nishimura Y, Yoshida A, Yonemori K, Motoi N, Tamura K, Hiraoka N, Mori T.

Pathol Int. 2018 Oct;68(10):563-566. doi: 10.1111/pin.12720. Epub 2018 Sep 14. Erratum in: Pathol Int. 2018 Dec;68(12):717.

PMID:
30216599
22.

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.

Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K.

Cancer Sci. 2018 Aug;109(8):2558-2566. doi: 10.1111/cas.13696. Epub 2018 Jul 28.

23.

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.

Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 10.1007/s00280-018-3617-5. Epub 2018 Jun 5.

24.

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.

Nagumo Y, Maejima A, Toyoshima Y, Komiyama M, Yonemori K, Yoshida A, Fujimoto H.

Int J Surg Case Rep. 2018;48:1-4. doi: 10.1016/j.ijscr.2018.04.027. Epub 2018 May 1.

25.

Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.

Kojima T, Asano Y, Kurasawa O, Hirata Y, Iwamura N, Wong TT, Saito B, Tanaka Y, Arai R, Yonemori K, Miyamoto Y, Sagiya Y, Yaguchi M, Shibata S, Mizutani A, Sano O, Adachi R, Satomi Y, Hirayama M, Aoyama K, Hiura Y, Kiba A, Kitamura S, Imamura S.

Bioorg Med Chem. 2018 May 15;26(9):2452-2465. doi: 10.1016/j.bmc.2018.04.008. Epub 2018 Apr 4.

PMID:
29669694
26.

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.

Ebata T, Shimoi T, Bun S, Miyake M, Yoshida A, Shimomura A, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Narita Y, Tamura K.

Oncology. 2018;94(6):340-344. doi: 10.1159/000486623. Epub 2018 Apr 3.

PMID:
29614488
27.

Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.

Kono M, Ochida A, Oda T, Imada T, Banno Y, Taya N, Masada S, Kawamoto T, Yonemori K, Nara Y, Fukase Y, Yukawa T, Tokuhara H, Skene R, Sang BC, Hoffman ID, Snell GP, Uga K, Shibata A, Igaki K, Nakamura Y, Nakagawa H, Tsuchimori N, Yamasaki M, Shirai J, Yamamoto S.

J Med Chem. 2018 Apr 12;61(7):2973-2988. doi: 10.1021/acs.jmedchem.8b00061. Epub 2018 Mar 14.

PMID:
29510038
28.

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.

Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S.

Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31.

29.

[I. Clinical Development and Prospect of Chemotherapy for Uterine Carcinosarcoma].

Nishikawa T, Yonemori K, Hasegawa K, Fujiwara Y, Fujiwara K.

Gan To Kagaku Ryoho. 2018 Feb;45(2):234-238. Japanese. No abstract available.

PMID:
29483412
30.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

31.

Collecting wrappers, labels, and packages to enhance accuracy of food records among children 2-8 years in the Pacific region: Children's Healthy Living Program (CHL).

Yonemori KM, Ennis T, Novotny R, Fialkowski MK, Ettienne R, Wilkens LR, Leon Guerrero RT, Bersamin A, Coleman P, Li F, Boushey CJ.

J Food Compost Anal. 2017 Dec;64(Pt 1):112-118. doi: 10.1016/j.jfca.2017.04.012. Epub 2017 Apr 23.

32.

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.

Support Care Cancer. 2018 Jul;26(7):2161-2166. doi: 10.1007/s00520-018-4054-z. Epub 2018 Jan 25.

PMID:
29372396
33.

Farnesoid X receptor antagonist exacerbates dyslipidemia in mice.

Amano Y, Yamakawa H, Yonemori K, Shimada M, Tozawa R.

Pharmacol Rep. 2018 Feb;70(1):172-177. doi: 10.1016/j.pharep.2017.07.010. Epub 2017 Jul 15.

PMID:
29367104
34.

Identification of novel quinazolinedione derivatives as RORγt inverse agonist.

Fukase Y, Sato A, Tomata Y, Ochida A, Kono M, Yonemori K, Koga K, Okui T, Yamasaki M, Fujitani Y, Nakagawa H, Koyama R, Nakayama M, Skene R, Sang BC, Hoffman I, Shirai J, Yamamoto S.

Bioorg Med Chem. 2018 Feb 1;26(3):721-736. doi: 10.1016/j.bmc.2017.12.039. Epub 2017 Dec 28.

PMID:
29342416
35.

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.

Okuma HS, Yonemori K.

Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13. Review.

PMID:
29282689
36.

Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.

Shirai J, Tomata Y, Kono M, Ochida A, Fukase Y, Sato A, Masada S, Kawamoto T, Yonemori K, Koyama R, Nakagawa H, Nakayama M, Uga K, Shibata A, Koga K, Okui T, Shirasaki M, Skene R, Sang B, Hoffman I, Lane W, Fujitani Y, Yamasaki M, Yamamoto S.

Bioorg Med Chem. 2018 Jan 15;26(2):483-500. doi: 10.1016/j.bmc.2017.12.006. Epub 2017 Dec 9.

PMID:
29262987
37.

TERT promoter hotspot mutations in breast cancer.

Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.

Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8.

38.

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8.

39.

Characterization of a gene regulatory network underlying astringency loss in persimmon fruit.

Nishiyama S, Onoue N, Kono A, Sato A, Yonemori K, Tao R.

Planta. 2018 Mar;247(3):733-743. doi: 10.1007/s00425-017-2819-0. Epub 2017 Nov 29.

PMID:
29188374
40.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.

Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Yoshida A, Fujiwara Y, Tamura K.

Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.

PMID:
29176397
41.

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.

Hirakawa A, Yonemori K, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N.

Cancer Sci. 2018 Jan;109(1):207-214. doi: 10.1111/cas.13436. Epub 2017 Dec 8.

42.

The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Yonemori K, Seki N, Idichi T, Kurahara H, Osako Y, Koshizuka K, Arai T, Okato A, Kita Y, Arigami T, Mataki Y, Kijima Y, Maemura K, Natsugoe S.

Oncotarget. 2017 Jul 26;8(41):70097-70115. doi: 10.18632/oncotarget.19591. eCollection 2017 Sep 19.

43.

The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.

Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Int J Gynecol Cancer. 2017 Nov;27(9):1850-1855. doi: 10.1097/IGC.0000000000001107.

PMID:
29040183
44.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
45.

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

46.

Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma.

Idichi T, Seki N, Kurahara H, Yonemori K, Osako Y, Arai T, Okato A, Kita Y, Arigami T, Mataki Y, Kijima Y, Maemura K, Natsugoe S.

Oncotarget. 2017 May 29;8(32):53180-53193. doi: 10.18632/oncotarget.18261. eCollection 2017 Aug 8.

47.

Impact of Snail and E-cadherin expression in pancreatic neuroendocrine tumors.

Yonemori K, Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Ueno S, Shinchi H, Natsugoe S.

Oncol Lett. 2017 Aug;14(2):1697-1702. doi: 10.3892/ol.2017.6306. Epub 2017 Jun 2.

48.

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3. No abstract available.

PMID:
28770275
49.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.

Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K.

ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.

50.

Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.

Sogabe S, Kamada Y, Miwa M, Niida A, Sameshima T, Kamaura M, Yonemori K, Sasaki S, Sakamoto JI, Sakamoto K.

ACS Med Chem Lett. 2017 May 10;8(7):732-736. doi: 10.1021/acsmedchemlett.7b00128. eCollection 2017 Jul 13.

Supplemental Content

Loading ...
Support Center